Teosal

Quick links to important sections

Teosal

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Teosal

Teosal is a brand name medication whose active ingredient is theophylline. Theophylline belongs to a class of drugs known as methylxanthines and acts as a bronchodilator. Its primary medical purpose is to manage and prevent symptoms related to chronic respiratory conditions where the airways are obstructed, such as asthma, chronic bronchitis, and emphysema, which are components of Chronic Obstructive Pulmonary Disease (COPD). Theophylline is often used as a second-line or add-on therapy.


Quick Facts

  • Active Ingredient: Theophylline
  • Drug Class: Methylxanthine (Bronchodilator)
  • Primary Uses: Chronic Obstructive Pulmonary Disease (COPD) and Asthma maintenance
  • Mechanism: Relaxes the smooth muscles of the bronchial airways

How Teosal Works

As a bronchodilator, Teosal (theophylline) works by causing the muscles surrounding the airways in the lungs to relax. This action opens the air passages, increasing airflow, and consequently helps to relieve symptoms like wheezing, shortness of breath, and chest tightness. The drug exerts its effects largely by acting as a nonselective phosphodiesterase inhibitor, which leads to the widening of the bronchial tubes. Theophylline is available in various formulations, including immediate-release and extended-release tablets or capsules, to accommodate different dosing schedules.

Regulatory References

  1. Theophylline - StatPearls - NCBI Bookshelf

What side effects are possible with Teosal?

Possible Side Effects and Safety Information for Teosal

This safety information is based on the profile of the similarly named hyaluronic acid dermal filler, Teosyal, as described in clinical study data and regulatory summary documents (such as FDA Summary of Safety and Effectiveness Data) for injectable medical devices.

Adverse Reaction Scope

The most frequently reported adverse reactions are localized Common Treatment Responses (CTR) occurring at the injection site. These reactions are typically transient, mild-to-moderate, and include:

  • Very Common (expected to affect more than 1 in 10 people): Redness, swelling (edema), pain, tenderness, bruising (ecchymosis), firmness (induration), itching, discoloration, and small lumps or bumps (masses).

Most of these local reactions resolve spontaneously within a few days to a week. The regulatory framework used for classifying adverse event System-Organ Classes (SOCs), such as Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Conditions, is the internationally recognized MedDRA (Medical Dictionary for Regulatory Activities).

Serious and Clinically Significant Adverse Reactions

Serious adverse reactions, though rare, are documented and include potential for vascular compromise (e.g., vessel occlusion or compression) which, if not promptly treated, can lead to severe outcomes like skin necrosis or, in extremely rare cases with facial fillers, vision impairment and stroke. Other serious events reported via post-market surveillance include inflammatory nodules, foreign body granulomas, abscess formation, and anaphylactic reactions (severe allergic response).

Safety-Related Restrictions

Contraindications restrict use in individuals with:

  1. A known history of hypersensitivity or allergy to any component of the product (including lidocaine).
  2. Active skin disease, inflammation, or infection at the proposed injection site.
  3. A known susceptibility to keloid formation or hypertrophic scarring.
  4. Pregnant or breast-feeding female subjects due to lack of established safety data.

Overdose and Emergency Response

Overdose and When to Seek Help

Teosal (theophylline) overdose is officially characterized by a progression of central nervous system (CNS) and cardiovascular effects, demanding immediate medical attention. Documented initial manifestations often include nausea, vomiting, restlessness, tremor, and sinus tachycardia. The toxicity profile is known to differ between acute overdose and chronic accumulation, with the latter potentially causing severe symptoms at lower serum levels.

Severe Manifestations and Required Action

Regulatory guidance identifies severe toxicity, which may escalate to life-threatening complications. These officially documented complications include seizures, ventricular tachycardia, and potential cardiac arrest. Significant laboratory abnormalities, such as hypokalemia and metabolic acidosis, are also noted in severe cases.

Immediate medical attention is required upon observing any signs of severe CNS or cardiac toxicity. Because no specific antidote is known, management focuses on supportive treatment. Officially described procedures may include administering activated charcoal for gastrointestinal decontamination and, for severe toxicity, considering hemodialysis to enhance drug elimination. Continuous ECG monitoring and theophylline serum concentration monitoring are required components of hospital observation.

Population Risk

The official label notes that the elderly, premature neonates, and patients with hepatic disease are documented to be at increased risk of toxicity due to altered drug clearance.

Therapeutic Uses of Teosal

What Teosal Treats: Main Uses and Benefits

Teosal (theophylline) provides supportive therapeutic benefit relevant for managing chronic airflow limitation and associated symptoms related to physical discomfort. It may be part of symptomatic management when additional support is needed for persistent symptoms in conditions like Chronic Obstructive Pulmonary Disease (COPD), chronic asthma, and the specialized neonatal condition Apnea of Prematurity. The medication is commonly used to help with breathing difficulty by relieving symptoms like wheezing and shortness of breath.


Symptom Relief and Functional Support

The medication may assist with easing symptom clusters that create noticeable physiological strain, specifically wheezing, shortness of breath (dyspnea), and uncomfortable chest tightness. It is generally applied as a long-term maintenance treatment when symptoms are not adequately addressed by other therapies. The therapeutic benefit is to offer symptomatic relief and support the patient during difficult episodes.

“Therapy is considered relevant for managing symptoms that interfere with daily comfort and may contribute to improved day-to-day comfort when breathing symptoms become more noticeable.”


Quick Fact: Relief for Airflow Obstruction Symptoms

The medication is used to manage symptoms related to physical discomfort, which supports the patient during symptomatic periods. This use contributes to easing the overall symptom load on a daily basis for patients with chronic lung conditions.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Teosal

Teosal (theophylline) eligibility is defined by official regulatory documentation to minimize the risk of toxicity, which is closely linked to how the body clears the drug. The medication is contraindicated for any individual with a known history of hypersensitivity to theophylline or to any related xanthine derivatives.

Use is generally allowed for most adults and adolescents, and for children mathbfge 1 year of age. Infants (especially those less than 1 year) and premature neonates may be eligible for specific uses, but they require intensive monitoring due to extremely slow and variable clearance rates.

The medication's use is strictly restricted for populations with conditions that reduce drug clearance. This includes older adults (mathbf> 60 years), patients with hepatic impairment (such as cirrhosis), or those with Congestive Heart Failure. Furthermore, official labeling requires caution for patients with active peptic ulcer disease or seizure disorders, as theophylline may exacerbate these conditions. Use during pregnancy (Category C) and lactation is conditional and only permitted after careful assessment and monitoring.

What should I know about interactions with other medicines?

Teosal (theophylline) has a well-documented interaction profile involving its metabolic clearance and pharmacodynamic actions. Regulatory documentation identifies specific combinations with strict constraints on co-administration.

Official Regulatory Restrictions

The co-administration of theophylline with the following substances is formally documented as either contraindicated or not recommended:

  • Riociguat and Febuxostat
  • Dipyridamole

Exposure Modification by Medicines and Substances

The majority of clinically relevant interactions are pharmacokinetic, altering theophylline clearance via the CYP1A2 enzyme system, leading to changes in systemic exposure:

  • Increased Concentration: CYP1A2 inhibitors, including certain antibiotics such as Ciprofloxacin and medicines such as Fluvoxamine, are officially documented to decrease theophylline clearance, thereby increasing its plasma concentration.
  • Reduced Concentration: Enzyme inducers, such as Rifampicin, Phenytoin, and the substance tobacco smoke, are documented to increase theophylline clearance, resulting in a reduced concentration.

Pharmacodynamic and Conditional Interactions

Additive effects are documented with other methylxanthines, such as caffeine, and sympathomimetics, which may potentiate stimulatory effects. The official profile also notes that physiological factors function as intrinsic interaction risks: reduced clearance is documented in the elderly, in patients with hepatic impairment or heart failure, or during periods of fever. For some formulations, a timing rule requires separating the dose from enteral (tube) feedings by one hour to manage absorption.

Mechanism of Action

Dual Molecular Action on Airway Smooth Muscle

Teosal exerts its action through two distinct mechanisms that converge to modulate the smooth muscle tone within the airways. Primarily, the drug functions as an inhibitor of the Phosphodiesterase (PDE) enzyme, while simultaneously acting as an antagonist at specific Adenosine Receptors. This dual intervention contributes to the modulation of bronchial muscle cells.


Intracellular and Receptor Pathway Modulation

PDE inhibition prevents the breakdown of the second messenger cyclic AMP (cAMP), leading to elevated intracellular cAMP levels. This rise initiates an intracellular cascade that promotes the relaxation of the airway smooth muscle. Concurrently, receptor antagonism blocks adenosine from binding and triggering pro-constrictive signals. This combined molecular activity results in the widening of the air passages (bronchodilation) as a final physiological consequence.

Dosage and Administration Information

Teosal is administered through two officially approved routes: the oral route for long-term chronic maintenance therapy and the intravenous (IV) route for acute clinical support in supervised settings. Oral administration includes both immediate-release and extended-release tablets or capsules. Extended-release tablets must be swallowed whole and must not be crushed, cut, or chewed to preserve the controlled release of the medication over time.

The medication's use follows a highly procedural, level-guided approach. Dosing is calculated initially based on ideal body weight, but the maintenance regimen is fundamentally guided by monitoring serum theophylline concentrations. The standard adult maintenance range typically falls between 400 mg/day to 600 mg/day, although this is individualized. Dose adjustments must be separated by intervals of no less than three days to allow drug concentrations to stabilize before the next adjustment is made.

Oral frequency is generally once or twice daily, and the patient is instructed to maintain consistency regarding meals, either always taking the dose with food or always without it. Specific patient populations, such as older adults or those with hepatic impairment, generally require a reduced maximum daily dose due to decreased drug clearance. If an oral dose is missed, the standard procedure is to skip the missed dose and take the next dose at the scheduled time, without taking a double amount.

Recent Clinical Evidence

Teosal: Recent Clinical Evidence


Evidence for Use in Stable Chronic Obstructive Pulmonary Disease (COPD)

Theophylline was studied for use in adults with stable COPD through randomized controlled trials (RCTs) and large observational studies. Research explored how theophylline was associated with changes in objective lung function measurements (such as FEV1) and outcomes reflecting daily functioning or activity level. Studies reported measurements related to lung function, but findings were mixed regarding consistent improvements in patient-reported outcomes. The follow-up durations were limited in many high-quality RCTs, meaning there is limited information for long-term outcomes.

Evidence for Use in Chronic Asthma Maintenance

Theophylline was evaluated in research as an add-on therapy for adults and children with chronic asthma. The studies explored outcomes reflecting episodic or acute changes, such as the frequency of asthma exacerbations and reported symptom control. Research describes patterns where the use of theophylline was associated with changes in pulmonary function. However, the evidence base is often based on older trials, and comparative evidence is lacking against many established inhaled therapies commonly used today.

Research on Use for Apnea of Prematurity (AOP)

Theophylline was studied for the specialized condition Apnea of Prematurity (AOP) in preterm neonates and infants through randomized controlled trials. The studies explored outcomes related to systemic or functional imbalance, such as the frequency of apneic events and the need for respiratory support. Trials reported patterns related to the measured frequency of apneic and bradycardic events. What remains uncertain is the long-term comparison against caffeine, as research describes a wider therapeutic safety window for the latter.

Long-Term Data and Research Gaps

Research on Teosal involves studies spanning from short-term trials to multi-year observational settings. While adults with moderate to severe COPD are commonly observed in studies, data for certain groups remain insufficient, particularly older adults with multiple health issues. The main research gap is the lack of current comparative evidence against established inhaled therapies. Regulatory bodies have noted that certainty remains low for some of the patient-reported outcomes, and long-term effects are not fully established.

Key Studies & References

  1. Chronic Use of Theophylline and Mortality in Chronic Obstructive Pulmonary Disease: A Meta-analysis
  2. Theophylline: MedlinePlus Drug Information (Authoritative Document)

Frequently Asked Questions (FAQ)

Common questions about Teosal (FAQ)

Q: Does Teosal have a generic version available?

A: Yes, Teosal's active ingredient, theophylline, is an established medication. According to official drug information, theophylline is available under various generic and multiple brand names.


Q: Is it normal to feel a change in appetite while on Teosal?

A: Official information lists loss of appetite as a potential adverse effect. In some cases, persistent nausea and vomiting may occur, which official documents describe as potentially being related to increased drug levels in the body.


Q: Can Teosal affect blood pressure?

A: Studies and official information indicate that theophylline can be associated with changes in cardiovascular function. This includes a fast, pounding, or irregular heartbeat and, with higher concentrations, symptoms like lightheadedness, which may be related to changes in blood pressure.


Q: Is Teosal used by children, and if so, how is it decided?

A: Theophylline is used in pediatric patients, including in premature infants for certain medical conditions. Dosage selection and careful monitoring are described as crucial because official information indicates that children, especially those under one year old, have highly variable and slow rates of clearing the drug from their bodies.


Q: Are there any long-term health concerns associated with Teosal?

A: Official warnings note that chronic use requires careful monitoring of the drug concentration in the blood. If levels remain consistently high, official documents indicate this can lead to cumulative toxicity, which may affect the neurological and cardiac systems.


Q: Can Teosal cause mood changes or anxiety?

A: Yes, adverse effects related to the central nervous system (CNS) have been reported with theophylline use. These effects include nervousness, anxiety, irritability, and other mood changes.


Q: How is Teosal different from a prescription painkiller?

A: According to official classification, Teosal (theophylline) is a methylxanthine bronchodilator, and its primary action is to relax the muscles around the airways. This function is distinct from the primary mechanism of analgesic (painkiller) drugs.


Q: Can I take Teosal if I have kidney problems?

A: While the liver is the main organ for clearing theophylline from the body, official guidance recommends caution and dose reduction in certain situations. Specifically, reduced clearance is a concern in infants with decreased renal (kidney) function, which may increase the risk of toxicity.


Q: What are the 'serious but rare' side effects of Teosal?

A: The most serious adverse reactions are typically associated with very high drug concentrations (toxicity). These include life-threatening cardiac events, such as sustained irregular heartbeats, and uncontrollable seizures.


Q: Does Teosal make birth control pills less effective?

A: Official drug interaction information indicates the opposite: oral contraceptives containing estrogen are documented to decrease theophylline clearance. This indicates that the contraceptive may lead to increased Teosal levels in the body, which can raise the risk of toxicity.


Q: What should I do if I feel dizzy after starting Teosal?

A: Official guidance describes that medical attention should be sought immediately if dizziness, lightheadedness, or other potential signs of drug toxicity occur.


Q: Is Teosal available as an injection, or only as a pill?

A: According to official product descriptions, the active ingredient is available for both oral use in the form of tablets or capsules, and for intravenous (IV) use (injection or infusion solution).


Q: Does the time of day matter when taking Teosal?

A: Some extended-release formulations are often intended for once-daily dosing. Official product labeling indicates that maintaining a consistent timing for the dose is important, particularly in relation to whether it is taken with or without food.


Q: Can I drive a car while taking Teosal?

A: Official warnings state that the medication can cause central nervous system effects, such as dizziness, confusion, and tremors. These effects are described as potentially impacting the ability to perform tasks that require mental alertness, such as driving.


Q: How quickly does Teosal leave your system?

A: The rate at which theophylline leaves the body is described as highly variable. In a healthy adult non-smoker, the average time for the drug concentration to decrease by half (half-life) is approximately 8.7 hours, but this can change significantly based on age, smoking status, and health conditions.


Q: Is it common for Teosal to cause headaches?

A: Yes, official safety information lists headache as one of the most common adverse events. This side effect is known to occur even when the drug concentration is within the intended therapeutic range.


Q: Can Teosal affect sleep quality?

A: Official product information lists CNS (central nervous system) stimulant effects, such as insomnia, sleeplessness, or general trouble sleeping, as potential side effects.


Q: Can I take Teosal while pregnant or breastfeeding?

A: Theophylline is classified as Pregnancy Category C; its use is conditional and allowed only after a careful risk assessment is performed, according to official guidance. The drug is excreted into breast milk, and official advice cautions about the potential for irritability in nursing infants.


Q: Are there different brand names for Teosal?

A: Yes, official drug registries confirm that the active ingredient theophylline is marketed under multiple brand names in addition to being widely available as a generic medication.

How should Teosal be stored and disposed of?

How to Store and Dispose of Teosal?

Storage and disposal instructions for Teosal (theophylline) must strictly follow regulatory guidance to ensure product stability and safety.

Storage Requirements

Requirement Official Condition
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Keep containers tightly closed and protect from air or moisture.
Child Safety Store safely out of the sight and reach of children.

Disposal Instructions

Expired or unused Teosal should be discarded using official methods. The preferred disposal method is through drug take-back programs or mail-back programs. If these are unavailable, follow government guidelines for disposal in household trash by mixing the medicine with an undesirable substance. Disposal must adhere to all local and federal regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Teosal found in:

A-Z Index: